L3.13 Kilder

Abirateron

Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistent prostate cancer (COU-AA-302): Final overfall survival analysis of a randomises, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152-60. 

Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomises, double-blind placebo-controlled, phase 3 trial. Lancet Oncol. 2019. Mar;20(3):408-419.

Analoger av gonadotropinfrigjørende hormon

Forlenget QT-tid og venøse tromboser som mulig bivirkning av anti-androgener, utredning fra RELIS 2012, http://www.relis.no/sok.aspx?q=qt-tid%20anti-androgener

Antiandrogener til onkologisk bruk

Helsedirektoratet. Nasjonale faglige retningslinjer for diagnostikk, behandling og oppfølgning av prostatakreft. Utgitt 11/2020. IS-2658. https://www.helsebiblioteket.no/retningslinjer/prostatakreft/forord

Dapagliflozin

Kato ET, Silverman MG, Mosenzon O, et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18. PMID: 30882238

Enzalutamid

Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424-33.

Ertugliflozin

SPC http://www.ema.europa.eu/docs/no_NO/document_library/EPAR_-_Product_Information/human/004315/WC500246918.pdf

Mekasermin

Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther 2009; 26(1): 40-54.

Perorale og parenterale antidiabetika

Helsedirektoratets retningslinjer for diabetes

Li S et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.

Palmer SC et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573